Impedance Cardiographic (ICG) Assessment of Pregnant Women With Severe Hypertension to Assess Impact of Standard Therapy
Information source: University of Mississippi Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pregnancy; Proteinuria, With Hypertension (Severe Pre-eclampsia); Delivery; Proteinuria, With Gestational Hypertension (Pre-eclampsia, Severe); Pregnancy; Hypertension, Gestational Hypertension, With Albuminuria (Severe Pre-eclampsia)
Phase: N/A
Status: Completed
Sponsored by: University of Mississippi Medical Center Official(s) and/or principal investigator(s):
James N Martin, MD, Principal Investigator, Affiliation: SOM-Obstetrics & Gynecology
Summary
The utilization of external cardiohemodynamic patient assessment, applying non-invasive
stick-on contact patches to the mother's neck on either side and chest wall on either side,
enables the practitioner to have information about the patient's cardiac function and
vascular status beyond simply blood pressure and pulse. This information, once collected,
should open the practitioner's eyes to better assess the patient's disease status and her
response to therapy. We will use this information to compare the effectiveness of the two
standard medications used for treatment of maternal high blood pressure.
Clinical Details
Official title: Impedance Cardiographic Assessment of Gravidas With Severe Hypertension (ICASH)to Assess Impact of Standard Therapy on Hemodynamic Parameters - A Pilot Study
Study design: Time Perspective: Prospective
Primary outcome: Usefulness of Impedance Cardiography (ICG) in pregnant women with hypertension
Detailed description:
Pregnant patients with severe acute hypertension due either to superimposed preeclampsia,
severe preeclampsia or severe gestational hypertension will be randomized to receive either
of two antihypertensive agents (hydralazine or labetalol). Just before drug administration
and immediately thereafter impedance cardiography of the patient will be undertaken and the
results analyzed relative to the cardiac profile and the drug administered to reduce the
severe hypertension.
Eligibility
Minimum age: 18 Years.
Maximum age: 45 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Nulliparous or parous patients with severe hypertension
- Singleton gestation
- Gestational age greater than 20 weeks
Exclusion Criteria:
- Multiple gestation
- Gestational age less than 20 weeks
Locations and Contacts
Wiser Hospital for Women and Infants at the University of Mississippi Medical Center, Jackson, Mississippi 39216, United States
Additional Information
Starting date: December 2009
Last updated: December 11, 2013
|
